 |
|
|
| |
INCREASED RATES OF HBV SEROCONVERSION UNDER
LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%]
|
| |
| |
Reported by Jules Levin
CROI 2017 Feb 13-16 Seattle, WA
Christoph Boesecke1,2, Fabian Busch1, Clara Lehmann2,3, Carolynne Schwarze-Zander1,2, Jakob Malin1,2, Jorg-Janne Vehreschild2,3,
Jan-Christian Wasmuth1,2, Gerd Fatkenheuer2,3, Jurgen K. Rockstroh1,2for the Cologne Bonn Cohort
1Bonn University Hospital, Bonn, Germany; 2) German Centre for Infection Research (DZIF), Cologne/Bonn, Germany; 3) CologneUniversity Hospital, Cologne, Germany
There was no significant correlation between HBsAg loss and gender (p=0.562), age(p=0.677), country of origin (p=0.274), CDC stage (p=0.585),CD4 cell count (p=0.249), CD4 gain (p=0.7), HBeAg (p=0.712), receivingTDF or TDF/3TC (p=0.576) or ART class (p=0.582).
|
| |
|
|
|
|
|
